Norvik Pharmaceuticals Private Limited
Imports, exports, and trades pharmaceutical and medical goods, including drugs, chemicals, and equipment.
2004 | Bangaluru, Karnataka (India) | Active
Norvik Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 21 Year, 1 Month
- Last Filing with ROC 31 Mar 2020
- Revenue Growth 14.70%
- Profit Growth 3.30%
- Ebitda -29.63%
- Net Worth -90.61%
- Total Assets 153.72%
About Norvik Pharmaceuticals
Norvik Pharmaceuticals Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 January 2004 and has a history of 21 years and one month. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Suma Kishore and Prema Munegowda serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231KA2004PTC033198
- Company No.
033198
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2004
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Pharma
Who are the key members and board of directors at Norvik Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suma Kishore  | Director | 16-Jan-2004 | Current |
| Prema Munegowda | Director | 16-Jan-2004 | Current |
Financial Performance of Norvik Pharmaceuticals.
Norvik Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 14.7% increase. The company also saw a slight improvement in profitability, with a 3.3% increase in profit. The company's net worth observed a substantial decline by a decrease of 90.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Norvik Pharmaceuticals?
In 2020, Norvik Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Norvik Pharmaceuticals?
Unlock and access historical data on people associated with Norvik Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Norvik Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Norvik Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.